Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study
1997

Combination Therapy for Ovarian Cancer

Sample size: 16 publication Evidence: moderate

Author Information

Author(s): GJ Veldhuis, PHB Willemse, JH Beijnen, H Boonstra, H Piersma, WTA van der Graaf, EGE de Vries

Primary Institution: University Hospital, Groningen

Hypothesis

Can a combination of paclitaxel, ifosfamide, and cisplatin with supportive factors improve outcomes in ovarian cancer patients?

Conclusion

The combination therapy showed low tolerability and unexpected mortality, but a tendency for faster platelet recovery with rhIL-3.

Supporting Evidence

  • Six of the nine evaluable patients had a tumour response.
  • The overall median progression-free survival was 7 months.
  • The overall mean survival was 13 months.
  • Grade IV neutropenia occurred in 12 out of 52 courses.
  • Patients treated with rhIL-3 showed a tendency to a faster platelet recovery.

Takeaway

Doctors tested a new treatment for ovarian cancer using three drugs together, but it made some patients very sick and had serious side effects.

Methodology

Patients received a combination of paclitaxel, ifosfamide, and cisplatin every 3 weeks, with some receiving additional rhIL-3.

Potential Biases

Potential selection bias due to the small number of patients and specific eligibility criteria.

Limitations

The study had a small sample size and high toxicity rates.

Participant Demographics

Patients aged 18-75 with histology-proven epithelial ovarian carcinoma.

Statistical Information

P-Value

P <0.001 for grade IV neutropenia and P=0.007 for gamma-glutamyltransferase.

Confidence Interval

95% CI 10-15 months for overall survival.

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication